Britain and America have announced a landmark trade agreement that will preserve no duties on UK drug products being sold in the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to raise funding on drugs through the National Health Service (NHS). This move ensures that duties on these vital exports will stay at zero for a timeframe of three years.
This development comes after recent statements to hike tariffs on patented pharmaceutical imports, with potential rates discussed as high as double the cost.
"This agreement between the United Kingdom strengthens the international landscape for innovative medicines and introduces long-overdue equity to American-British drug exports," a statement said.
Commercial Significance
Pharmaceuticals constitute one of the Britain's most significant exports to the America, which is by far the biggest buyer for major companies like GSK and AstraZeneca.
Export figures reveal that in the year leading up to the third quarter, the UK shipped drugs worth £11.1bn to the US. This value made up 17.4% of total UK exports in that period.
"This agreement safeguards work, stimulates investment and paves the way for the UK to establish itself as a global hub for biotech and pharma," a government official commented.
Detailed UK Commitments
The agreement entails several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to increase total health service expenditure on drugs from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, rebates were more than twenty percent.
Industry Background
The deal comes amid a protracted dispute between the drug companies and the UK government over medicine costs and NHS adoption.
These tensions were heightened by assertions that American consumers were paying a premium for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several large drug company projects in the UK have been halted or scrapped, while substantial expansions have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a share of its resources over the previous ten-year period.
